Login to Your Account

Genta's Stock Slides Again As ODAC Turns Back Genasense

By Aaron Lorenzo

Thursday, September 7, 2006
SILVER SPRING, Md. - The FDA's Oncology Drugs Advisory Committee on Wednesday rejected Genta Inc.'s new drug application for Genasense (oblimersen sodium) to treat relapsed or refractory chronic lymphocytic leukemia, driving down the company's stock value for a second consecutive day. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription